中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

151 records (took 0.039 seconds)

    DIRECT CHOLESTEROL ASSAY
    61.
    发明申请
    DIRECT CHOLESTEROL ASSAY 审中-公开
    直接胆固醇测定

    公开(公告)号：WO1995002826A1

    公开(公告)日：1995-01-26

    申请号：PCT/US1994007836

    申请日：1994-07-13

    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

    Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  PURDIE, Neil

    IPC: G01N33/92

    CPC classification number: G01N21/19 ,  G01N33/92 ,  G01N2800/044

    Abstract: The present invention relates to the direct quantitative determination of cholesterol and involves the formation of a spectrophotometrically active product of cholesterol obtained by contacting cholesterol with an acyl compound and a perchlorate effective to form the spectrophotometrically active product.

    Abstract translation: 本发明涉及胆固醇的直接定量测定，并涉及通过使胆固醇与有效形成分光光度学活性产物的酰基化合物和高氯酸盐接触而获得的胆固醇的分光光度学活性产物的形成。

    GROUP II-VI COMPOUND SEMICONDUCTOR LIGHT EMITTING DEVICES AND AN OHMIC CONTACT THEREFOR
    62.
    发明申请
    GROUP II-VI COMPOUND SEMICONDUCTOR LIGHT EMITTING DEVICES AND AN OHMIC CONTACT THEREFOR 审中-公开
    II-VI族化合物半导体发光器件及其OHMIC接触器

    公开(公告)号：WO1994015369A1

    公开(公告)日：1994-07-07

    申请号：PCT/US1993012545

    申请日：1993-12-22

    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

    Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  GUNSHOR, Robert, L. ,  NURMIKKO, Arto, V. ,  HE, Li ,  FAN, Yongping ,  HAN, Jung

    IPC: H01L33/00

    CPC classification number: H01S5/347 ,  B82Y20/00 ,  H01L21/02395 ,  H01L21/024 ,  H01L21/02417 ,  H01L21/02469 ,  H01L21/02485 ,  H01L21/0251 ,  H01L21/02557 ,  H01L21/0256 ,  H01L21/02562 ,  H01L21/02568 ,  H01L21/02576 ,  H01L21/02579 ,  H01L21/44 ,  H01L27/156 ,  H01L33/06 ,  H01L33/08 ,  H01L33/14 ,  H01L33/26 ,  H01L33/28 ,  H01L33/40 ,  H01S5/0421 ,  H01S5/2231

    Abstract: Group II-VI compound semiconductor light emitting devices which include at least one II-VI quantum well region of a well layer disposed between first and second barrier layers is disclosed. The quantun well region is sandwiched between first and second cladding layers of a II-VI semiconductor material. The first cladding layer is formed on and lattice matched to the first barrier layer and to a substrate of a III-V compound semiconductor material. The second cladding layer is lattice matched to the second barrier layer. The quantum well layer comprises a II-VI compound semiconductor material having the formula AxB(1-x)C wherein A and B are two different elements from Group II and C is at least one element from Group VI. When the second cladding layer has a p-type conductivity, a greaded bandgap ohmic contact according to the present invention can be utilized. The graded bandgap contact can be a single continuously graded II-VI p-type region or a plurality of cells with each of the cells having first and second thin layers of first and second p-type II-VI semiconductor materials respectively. Another embodiment of the present invention discloses a monolithic multicolor light emitting element capable of emitting four colors and a method for fabricating same. The monolithic multicolor element includes four II-VI semiconductor light emitting devices formed on a single III-V substrate.

    Abstract translation: 公开了包括设置在第一和第二阻挡层之间的阱层的至少一个II-VI量子阱区的II-VI族化合物半导体发光器件。 量子阱区夹在II-VI半导体材料的第一和第二覆层之间。 第一包层与第一阻挡层和III-V族化合物半导体材料的衬底形成并晶格匹配。 第二包层与第二阻挡层晶格匹配。 量子阱层包括具有式AxB（1-x）C的II-VI化合物半导体材料，其中A和B是来自组II的两个不同元素，C是来自第VI族的至少一种元素。 当第二覆层具有p型导电性时，可以利用根据本发明的带状带隙欧姆接触。 分级带隙接触可以是单个连续分级的II-VI p型区域或多个单元，其中每个单元分别具有第一和第二p型II-VI半导体材料的第一和第二薄层。 本发明的另一实施例公开了能够发射四种颜色的单片多色发光元件及其制造方法。 单片多色元件包括形成在单个III-V衬底上的四个II-VI半导体发光器件。

    PENTAVALENT SYNTHESIS OF OLIGONUCLEOTIDES CONTAINING STEREOSPECIFIC ALKYLPHOSPHONATES AND ARYLPHOSPHONATES
    64.
    发明申请
    PENTAVALENT SYNTHESIS OF OLIGONUCLEOTIDES CONTAINING STEREOSPECIFIC ALKYLPHOSPHONATES AND ARYLPHOSPHONATES 审中-公开
    含有立体烷基磷酸酯和芳基磷酸酯的寡核苷酸的合成

    公开(公告)号：WO1994000473A2

    公开(公告)日：1994-01-06

    申请号：PCT/US1993006277

    申请日：1993-06-30

    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

    Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  WICKSTROM, Eric ,  LEBEDEV, Alexander V.

    IPC: C07H21/00

    CPC classification number: C12N15/113 ,  C07H21/00 ,  C12N2310/321 ,  C12Q1/6813 ,  C12Q1/6886

    Abstract: The present invention provides a method for making R stereospecific alkyl- and aryl-phosphonate linkages between nucleotides. These methods can be used for automated synthesis of oligonucleotides having sequential R stereospecific alkyl- and aryl-phosphonate linkages. The present invention is also directed to the oligonucleotides having several sequential R phosphonate linkages which were produced by the subject methods. Moreover, the present invention provides methods for using the subject oligonucleotides, including methods for regulating the biosynthesis of a DNA, an RNA or a protein and methods for detecting and isolating complementary nucleic acid targets.

    Abstract translation: 本发明提供了在核苷酸之间制备R立体特异性烷基 - 和芳基 - 膦酸酯键的方法。 这些方法可用于自动合成具有顺序R立体特异性烷基 - 和芳基 - 膦酸酯键的寡核苷酸。 本发明还涉及通过本发明方法制备的具有多个连续的R膦酸酯键的寡核苷酸。 此外，本发明提供了使用本发明的寡核苷酸的方法，包括调节DNA，RNA或蛋白质的生物合成的方法以及用于检测和分离互补核酸靶的方法。

    HIGH PERFORMANCE CHIRAL SELECTOR
    65.
    发明申请
    HIGH PERFORMANCE CHIRAL SELECTOR 审中-公开
    高性能手表选择器

    公开(公告)号：WO1994000408A1

    公开(公告)日：1994-01-06

    申请号：PCT/US1993005933

    申请日：1993-06-22

    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

    Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  PIRKLE, William, H. ,  WELCH, Christopher, J. ,  BOWEN, William, E. ,  YANG, Qing

    IPC: C07B57/00

    CPC classification number: C07C233/83 ,  B01J20/3204 ,  B01J20/3219 ,  B01J20/3227 ,  B01J20/3248 ,  B01J20/3251 ,  B01J20/3253 ,  C07B57/00 ,  C07C237/22

    Abstract: A high performance chiral selector having formula (I) whereinAr is a monocyclic or ortho-fused polycyclic aromatic moiety having up to 10 ring carbon atoms, either of which may be unsubstituted or substituted with one or more C1 to C6 alkyl, C1 to C6 alkoxy, NO2, N(R5)3, CN, COOR6, SO3H and COR7 groups wherein R5, R6 and R7 are each independently hydrogen or C1 to C6 alkyl; R1 and R2 are each independently hydrogen, C1 to C6 alkyl or phenyl; R3 and R4 are each independently C1 to C12 alkyl or C2 to C12 alkenyl; and m and n are each independently zero or 1, said compound being an R or an S enantiomer or a mixture of R and S enantiomers.

    Abstract translation: 具有式（I）的高性能手性选择剂，其中Ar是具有至多10个环碳原子的单环或邻 - 稠合多环芳族部分，其中任一个可以是未取代的或被一个或多个C 1至C 6烷基，C 1至C 6烷氧基 ，NO 2，N（R 5）3，CN，COOR 6，SO 3 H和COR 7基团，其中R 5，R 6和R 7各自独立地为氢或C 1至C 6烷基; R 1和R 2各自独立地为氢，C 1至C 6烷基或苯基; R 3和R 4各自独立地为C 1至C 12烷基或C 2至C 12烯基; 并且m和n各自独立地为0或1，所述化合物是R或S对映体或R和S对映异构体的混合物。

    HUMAN EPIDERMAL GENE PROMOTER
    68.
    发明申请
    HUMAN EPIDERMAL GENE PROMOTER 审中-公开
    人造丝基因促进剂

    公开(公告)号：WO1993015209A1

    公开(公告)日：1993-08-05

    申请号：PCT/US1993000537

    申请日：1993-01-22

    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

    Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  POLAKOWSKA, Renata, Regina ,  GOLDSMITH, Lowell, Alan

    IPC: C12N15/54

    CPC classification number: C12N9/1044 ,  C12N15/63 ,  C12N15/85 ,  C12N2830/008 ,  C12N2830/85

    Abstract: The present invention relates to promoter elements from human type I transglutaminase (TGase I) genes for controlled gene expression of both human TGase I and heterologous proteins. These promoter elements permit tissue-specific expression of genes, e.g. for use in human gene therapy and for testing pharmaceutical agents with artificial skin. Additionally, the subject promoter elements can provide differential regulation under physiological conditions or in the presence of exogenously added factors including calcium and retinoic acid.

    Abstract translation: 本发明涉及来自人类I型谷氨酰胺转移酶（TGase I）基因的启动子元件，用于人TGase I和异源蛋白质的受控基因表达。 这些启动子元件允许基因的组织特异性表达，例如。 用于人类基因治疗和用人造皮肤测试药剂。 此外，受试者启动子元件可以在生理条件下或在外源性加入的因子（包括钙和视黄酸）的存在下提供差异调节。

    METHOD AND APPARATUS FOR ALLEVIATING AND DIAGNOSING SYMPTOMS OF HEART BLOCK
    69.
    发明申请
    METHOD AND APPARATUS FOR ALLEVIATING AND DIAGNOSING SYMPTOMS OF HEART BLOCK 审中-公开
    用于记录和诊断心脏块症状的方法和装置

    公开(公告)号：WO1993014814A1

    公开(公告)日：1993-08-05

    申请号：PCT/US1993000509

    申请日：1993-01-21

    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

    Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  SCHERLAG, Benjamin, J.

    IPC: A61N01/362

    CPC classification number: A61N1/365 ,  A61N1/368

    Abstract: A method for alleviating and diagnosing syndromes of heart block wherein a stimulus is continuously or intermittently delivered via a single electrode catheter at a site in a heart in close proximity to the A-V junction in the heart. The subthreshold stimuli were sufficient to cause impulses in the atrium to pass through the damaged his bundle to the ventricle and the stimuli were set at a level below a level required to excite the heart tissue. The delivery of the stimuli alleviates the symptoms of heart block. In one application, the delivery of the stimuli is used for diagnosing heart block when delivery of the stimuli induces the symptoms of heart block in the patient with partial or covert conduction disease.

    Abstract translation: 一种用于减轻和诊断心脏阻塞综合征的方法，其中刺激在心脏中靠近心脏中的A-V结的心脏中的位置经由单个电极导管连续或间歇递送。 亚阈值刺激足以使心房中的脉冲通过损伤的束到心室，并且将刺激设定在低于激发心脏组织所需水平的水平。 刺激物的传递减轻了心脏阻塞的症状。 在一个应用中，当部分或隐性传导疾病患者的输送刺激引起心脏阻塞的症状时，刺激的递送被用于诊断心脏阻塞。

    ADENO-ASSOCIATED VIRUS-2 BASAL VECTORS
    70.
    发明申请
    ADENO-ASSOCIATED VIRUS-2 BASAL VECTORS 审中-公开
    ADENO相关病毒-2基本矢量

    公开(公告)号：WO1993009239A1

    公开(公告)日：1993-05-13

    申请号：PCT/US1992009769

    申请日：1992-11-06

    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

    Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  SRIVASTAVA, Arun

    IPC: C12N15/86

    CPC classification number: C12N15/86 ,  A61K38/00 ,  A61K48/00 ,  C07K14/805 ,  C12N15/90 ,  C12N2750/14143

    Abstract: Gene therapy involves the transfer and stable insertion of new genetic information into cells. The present invention is directed to safe vectors for gene therapy and thus provides hybrid parvovirus vectors which are capable of site-specific integration into a mammalian chromosome without substantial cytotoxicity, and which direct erythroid cell-specific expression of heterologous genes. The hybrid vector is useful in gene therapy, particularly in the treatment of hemoglobinopathies and other hematopoietic diseases, and in conferring cell-specific multidrug resistance. A method of delivery of constitutive levels of a pharmaceutical product and a method of producing a recombinant protein are also provided.

Patent Agency Ranking